Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study

J Endocrinol Invest. 2021 Jun;44(6):1243-1252. doi: 10.1007/s40618-020-01415-1. Epub 2020 Sep 6.

Abstract

Background: The aim of this pragmatic intervention study was to investigate changes in cardiometabolic outcomes, irisin plasma concentration, and body composition during a 4-month intervention in unselected obese individuals.

Materials and methods: In 111 obese women aged 36.73 ± 7.2 years, we measured changes in weight, lipid profiles, glucose, insulin, Homeostatic Model Assessment-Insulin Resistance Index (HOMA-IR), uric acid, aminotransferases, and irisin. Body composition including lean mass (LM) and total (TF), gynoid (GF), android (AF), and visceral fat (VF) was assessed using densitometry. Physical activity was assessed using the International Physical Activity Questionnaire (IPAQ). The participants received tailored written advice targeting lifestyle according to current guidelines. At follow-up, patients rated their adherence in the self-administered questionnaire.

Results: Mean weight loss in the whole group was 3.12 kg (- 3.3%); 26% of the women achieved the desired target of weight loss (> 5% of the initial weight), whereas weight decreased moderately in 50% and increased in 14%. In 86 women with weight loss, there were significant changes in HOMA-IR (- 13.8%), insulin (- 11.2%), alanine aminotransferase (- 8.0%), VF (- 7.0%), AF (- 5.4%), TF (- 4.7%), GF (- 2.8%) and LM (- 1.5%), whereas irisin and HDL-C levels and the mean IPAQ score did not change.

Conclusions: In this real-world evidence study, a successful weight loss achieved only 26% of patients, with overall much better adherence to diet restriction than to exercise. However, even mild to moderate weight loss resulted in significant improvements in cardiometabolic health. Weight loss was associated with a modest LM decrease but did not influence plasma irisin.

Keywords: Cardiometabolic health; Irisin; Real-world study; Weight loss.

Publication types

  • Pragmatic Clinical Trial

MeSH terms

  • Adult
  • Blood Glucose / analysis
  • Body Composition
  • Body Mass Index
  • Cardiometabolic Risk Factors
  • Cardiovascular Diseases / prevention & control
  • Densitometry / methods
  • Diet Therapy* / methods
  • Diet Therapy* / psychology
  • Exercise / psychology*
  • Female
  • Fibronectins / blood*
  • Humans
  • Insulin / blood
  • Obesity* / diagnosis
  • Obesity* / metabolism
  • Obesity* / psychology
  • Obesity* / therapy
  • Outcome Assessment, Health Care
  • Risk Reduction Behavior*
  • Weight Loss / physiology*

Substances

  • Blood Glucose
  • FNDC5 protein, human
  • Fibronectins
  • Insulin